Journal of Cancer Science and Research
Open Access

Tamura N

Publications

• Research Article
  Prognostic Factors for Non-small Cell Lung Cancer Treated with Carboplatin, Paclitaxel, and Bevacizumab
  Author(s): Kazuyori T*, Tamura N, Kojima A and Kuwano KKazuyori T*, Tamura N, Kojima A and Kuwano K
  
  Background and objective: Carboplatin, paclitaxel, and bevacizumab (CPB) therapy is a treatment option for non-small cell lung cancer. Factors predicting the survival of patients receiving this therapy were investigated. Methods: From 2011 to 2016, 41 patients (excluding those positive for EGFR mutation or ALK fusion gene) received first-line CPB therapy. Prognostic factors for progression-free survival (PFS) and overall survival (OS) were investigated by the Cox proportional hazards model. Results: The median age was 70 years, 38 patients had adenocarcinoma, and 30 patients were men. Eastern Cooperative Oncology Group performance status (PS) was 0 /1 /2 in 10/ 29/2 patients. Overall PFS and OS were 6.4 and 10.9 months, respectively. According to univariate analysis, a neutrophil/lymphocyte ratio (NLR)>3.0 and hypoalb.. View More»
  DOI: 10.4172/2576-1447.1000110

  Abstract PDF

Relevant Topics